A pooled analysis of six month comparative efficacy and tolerability in four randomized clinical trials: agomelatine versus escitalopram, fluoxetine, and sertraline

Mar 12, 2013CNS spectrums

Six-month comparison of effectiveness and side effects between agomelatine and three common antidepressants

AI simplified

Long Covid on OpenScience ↗PubMed ↗DOI ↗

Abstract

Patients treated with agomelatine had a significantly lower final Hamilton Depression Rating Scale (HAM-D) score compared to those treated with selective serotonin reuptake inhibitors (SSRIs).

Agomelatine demonstrated higher HAM-D response rates at 24 weeks compared to SSRIs in patients with severe depression.
Final Clinical Global Impression of Improvement (CGI-I) scores were significantly lower for agomelatine than for SSRIs.
Numerically higher response and remission rates were observed for agomelatine without reaching statistical significance.
Fewer patients treated with agomelatine discontinued due to adverse events compared to those on SSRIs, although this difference was not statistically significant.

AI simplified

OBJECTIVE: A pooled-analysis on the long-term outcome in four head-to-head studies: agomelatine versus fluoxetine, sertraline, and (twice) escitalopram. Method A meta-analytic approach was used. Hamilton Depression Rating Scale (HAM-D) scores, response and remission rates, Clinical Global Impression of Improvement (CGI-I) scores, response and remission rates, and completion rates/discontinuation rates due to adverse events were analyzed.

RESULTS: At the last post-baseline assessment on the 24-week treatment period, the final HAM-D-17 score was significantly lower in patients treated with agomelatine than in patients treated with selective serotonin reuptake inhibitors (SSRIs), as well in the total group of patients with severe depression (P = 0.014 and 0.040, respectively). HAM-D response rates at the end of 24 weeks were significantly higher in patients treated with agomelatine than in patients treated with SSRIs, as well in the total group of patients with severe depression (P = 0.031 and 0.048, respectively). HAM-D remission rates at the end of 24 weeks were numerically but not significantly higher in patients treated with agomelatine than in patients treated with SSRIs. Final CGI-I scores were significantly lower for agomelatine. CGI-I response as well as remission rates were numerically higher in patients treated with agomelatine, without statistical significance. The percentage of patients with at least one emergent adverse event leading to treatment discontinuation was 9.4% in patients treated with SSRIs and 6.6% in patients treated with agomelatine (P = 0.065).

CONCLUSION: The present pooled analysis shows that, from a clinical point of view, agomelatine is at least as efficacious as the investigated SSRIs with a trend to fewer discontinuations due to adverse events.

Full Text

Full text is available at the source.

View full text ↗

A pooled analysis of six month comparative efficacy and tolerability in four randomized clinical trials: agomelatine versus escitalopram, fluoxetine, and sertraline

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the long covid brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the long covid brief